title: Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, University of Indonesia - dr. Cipto Mangunkusumo Hospital, Jakarta Pusat 10430, Indonesia. hom_fkui@yahoo.com
authors.forename: Ary H
authors.initials: AH
authors.lastname: Reksodiputro
authors.forename: Syafrizal
authors.initials: S
authors.lastname: Syafei
authors.forename: Nugroho
authors.initials: N
authors.lastname: Prayogo
authors.forename: Bambang
authors.initials: B
authors.lastname: Karsono
authors.forename: Ikhwan
authors.initials: I
authors.lastname: Rinaldi
authors.forename: Wulyo
authors.initials: W
authors.lastname: Rajabto
authors.forename: Nadia A
authors.initials: NA
authors.lastname: Mulansari
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007214:Indonesia; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate